Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | Controller & PAO | October 15, 2019 | October 17, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date October 15, 2019 · Filed October 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 270 |
Ending reported balance
After 2019-10-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-10-15 · Exercise / conversion · Acquired 417 · Balance 417 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2019-10-15 · Sale · Disposed 147 · Balance 270 F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,254 |
Reported balance
After 2019-10-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-10-15 · Exercise / conversion · Disposed 417 · Balance 1,254 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3: The restricted stock units vest in four equal annual installments beginning 10/15/19. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3: The restricted stock units vest in four equal annual installments beginning 10/15/19.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 15, 2019 Filed Oct 17, 2019 22:26 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 417 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053494 · doc4.xml · derivative · entry 3 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,254 Underlying: Common Stock · 417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 22:26 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 147 | $39.65 | $5,828.55 |
DisclosureSEC source: 0001209191-19-053494 · doc4.xml · nonDerivative · entry 2 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 22:26 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053494 · doc4.xml · nonDerivative · entry 1 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 11, 2019 Filed Sep 11, 2019 23:19 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 4,645 | $41.18 | $191,281.10 |
DisclosureSEC source: 0001209191-19-049231 · doc4.xml · nonDerivative · entry 8 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.1401 to $41.255, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 23:19 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,972 | $0.00 Strike: $16.50 | $0.00 |
DisclosureSEC source: 0001209191-19-049231 · doc4.xml · derivative · entry 14 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,598 Underlying: Common Stock · 1,972 shares Expires 2028-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on April 7, 2019, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 23:19 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,593 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001209191-19-049231 · doc4.xml · derivative · entry 13 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,594 Underlying: Common Stock · 4,593 shares Expires 2027-09-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on September 7, 2018, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 23:19 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,439 | $0.00 Strike: $36.54 | $0.00 |
DisclosureSEC source: 0001209191-19-049231 · doc4.xml · derivative · entry 12 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,911 Underlying: Common Stock · 4,439 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 8, 2018, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 23:19 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,063 | $0.00 Strike: $29.24 | $0.00 |
DisclosureSEC source: 0001209191-19-049231 · doc4.xml · derivative · entry 11 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552 Underlying: Common Stock · 6,063 shares Expires 2026-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on January 1, 2017, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 23:19 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,900 | $0.00 Strike: $32.28 | $0.00 |
DisclosureSEC source: 0001209191-19-049231 · doc4.xml · derivative · entry 10 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,900 shares Expires 2025-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 23:19 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $20.65 | $0.00 |
DisclosureSEC source: 0001209191-19-049231 · doc4.xml · derivative · entry 9 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2024-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 23:19 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 28,467 | $39.49 | $1,124,161.83 |
DisclosureSEC source: 0001209191-19-049231 · doc4.xml · nonDerivative · entry 7 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,645 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.49 to $39.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 23:19 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,972 | $16.50 | $32,538.00 |
DisclosureSEC source: 0001209191-19-049231 · doc4.xml · nonDerivative · entry 6 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 23:19 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 4,593 | $35.80 | $164,429.40 |
DisclosureSEC source: 0001209191-19-049231 · doc4.xml · nonDerivative · entry 5 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 23:19 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 4,439 | $36.54 | $162,201.06 |
DisclosureSEC source: 0001209191-19-049231 · doc4.xml · nonDerivative · entry 4 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 23:19 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,063 | $29.24 | $177,282.12 |
DisclosureSEC source: 0001209191-19-049231 · doc4.xml · nonDerivative · entry 3 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 23:19 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 3,900 | $32.28 | $125,892.00 |
DisclosureSEC source: 0001209191-19-049231 · doc4.xml · nonDerivative · entry 2 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 23:19 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 7,500 | $20.65 | $154,875.00 |
DisclosureSEC source: 0001209191-19-049231 · doc4.xml · nonDerivative · entry 1 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 860 shares of the Issuer's common stock acquired by the reporting person on November 15, 2018 and 573 shares of the Issuer's common stock acquired by the reporting person on May 15, 2019 pursuant to an employee stock purchase program. Read SEC document |
| April 29, 2019 Filed May 1, 2019 22:02 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 3,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-026848 · doc4.xml · derivative · entry 2 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,442 Underlying: Common Stock · 3,442 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. Read SEC document |
| April 29, 2019 Filed May 1, 2019 22:02 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 6,039 | $0.00 Strike: $25.12 | $0.00 |
DisclosureSEC source: 0001209191-19-026848 · doc4.xml · derivative · entry 1 Miller Eric Alejandro · CIK 0001758494 · Controller & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,039 Underlying: Common Stock · 6,039 shares Expires 2029-04-29 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 29, 2020. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.